Nectar Lifesciences Ltd.
Snapshot View

View in App

Prices View details >>

15.16 +0.56 ▲3.8%

29 March 2023, 04:01:00 PM
Volume: 31,365

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.neclife.com
Market Cap 336.84 Cr.
Enterprise Value(EV) 1,112.41 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) -0.72 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-12
Industry PE 32.17 Trailing Twelve Months Ending 2022-12
Book Value / Share 47.27 Trailing Twelve Months Ending 2022-12
Price to Book Value 0.32 Calculated using Price: 15.16
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 22.43 Cr. 224,260,970 Shares
FaceValue 1
Company Profile
Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv Goyal.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+3.84%
1 Week
-7.11%
1 Month
-12.37%
3 Month
-40.20%
6 Month
-27.46%
1 Year
-37.87%
2 Year
-18.93%
5 Year
-42.68%
10 Year
-3.13%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 6.92 7.17 5.78 5.64 5.06 4.40 2.84 -6.67 2.33
Return on Capital Employed (%) 12.24 11.58 9.95 9.73 9.13 10.29 8.32 1.41 5.77
Return on Assets (%) 2.66 2.70 2.14 2.15 1.97 1.75 1.19 -2.93 1.05

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 927 958 954 1,007 1,059 1,105 1,136 1,062 1,088 1,069
Non Curr. Liab. 341 397 362 296 356 300 249 126 296 264
Curr. Liab. 1,126 1,156 1,240 1,279 1,309 1,300 1,248 1,187 1,004 944
Minority Int.
Equity & Liab. 2,394 2,510 2,556 2,581 2,724 2,705 2,633 2,376 2,388 2,278
Non Curr. Assets 1,157 1,106 1,092 1,085 1,063 1,036 1,018 1,137 1,033 1,001
Curr. Assets 1,237 1,369 1,464 1,496 1,661 1,669 1,615 1,239 1,355 1,276
Misc. Exp. not W/O 0 36
Total Assets 2,394 2,510 2,556 2,581 2,724 2,705 2,633 2,376 2,388 2,278

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 1,638 1,644 1,676 1,644 1,876 2,783 2,366 1,543 1,669 1,612
Other Income 13 20 6 23 6 6 4 11 11 25
Total Income 1,651 1,664 1,681 1,666 1,882 2,789 2,371 1,555 1,680 1,637
Total Expenditure -1,350 -1,377 -1,437 -1,419 -1,640 -2,519 -2,147 -1,442 -1,510 -1,527
PBIDT 300 287 245 247 242 270 224 113 170 110
Interest -138 -126 -123 -117 -115 -148 -126 -112 -79 -77
Depreciation -84 -77 -57 -62 -64 -63 -61 -60 -57 -59
Taxation -16 -18 -10 -12 -10 -11 -6 12 -9 10
Exceptional Items -25
PAT 62 66 54 55 52 48 32 -73 25 -16
Minority Interest
Share Associate
Other Related Items 1
Consolidated Net Profit 62 66 54 55 52 48 32 -73 25 -16
Adjusted EPS 3 3 2 2 2 2 1 -3 1 -1

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 361 255 144 169 199 65 239 285 21 95
Cash Fr. Inv. -99 -90 -60 -77 -18 -29 -26 -33 -29 17
Cash Fr. Finan. -282 -161 -61 -89 -204 -40 -201 -252 11 -119
Net Change -20 4 23 3 -23 -4 12 0 4 -8
Cash & Cash Eqvt 6 10 33 37 13 9 21 21 26 18

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 55.80 55.80 55.80 55.80 55.80 55.80 55.80 55.80 55.80
Public 44.20 44.20 44.20 44.20 44.20 44.20 44.20 44.20 44.20
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00

Announcements View Details >>

Wed, 15 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Financial Results of the Company for the quarter ended on December 31 2022 which have been published in the following newspapers:1. Business Standard (English-all editions) dated 15.02.2023.2. Desh Sewak (Punjabi) dated 15.02.2023.
Tue, 14 Feb 2023
Appointment of Company Secretary and Compliance Officer
Appointment of Ms. Neha Vaishnav as the Company Secretary of the Company w.e.f. February 14 2023
Tue, 14 Feb 2023
The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Period Ended December 31 2022
The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months period ended December 31 2022 which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

Technical Scans View Details >>

Wed, 29 Mar 2023
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Week Low Close Below Last Week Low

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 237,702.12 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. 76,011.65 4,564.50 +0.8%
Divi's Laboratories Ltd. 74,827.63 2,818.70 +0.5%
Cipla Ltd. 71,662.87 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. 62,756.97 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. 52,113.83 1,554.65 +0.7%
Zydus Lifesciences Ltd. 49,628.37 490.30 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.44 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.86 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 31.22 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 27.16 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 82.20 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 63.32 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.08 490.30 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.30 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.45 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-12 6.01 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-12 3.16 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.19 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.25 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.88 490.30 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 0.04 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 490.30 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 13.10 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 490.30 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 490.30 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 990.70 +0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,564.50 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,818.70 +0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 887.85 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,371.75 +1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,554.65 +0.7%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 490.30 +1.2%

FAQ's On Nectar Lifesciences Ltd.

What is Nectar Lifesciences share price?
Can I buy Nectar Lifesciences shares now?
What is the Market Cap of Nectar Lifesciences?
What are the key metrics to analyse Nectar Lifesciences?
What is the 52 Week High and Low of Nectar Lifesciences?
What is the trend of Nectar Lifesciences share price?